In:
Molecular Syndromology, S. Karger AG, Vol. 5, No. 3-4 ( 2014), p. 187-197
Abstract:
For a number of years, coenzyme Q 〈 sub 〉 10 〈 /sub 〉 (CoQ 〈 sub 〉 10 〈 /sub 〉 ) was known for its key role in mitochondrial bioenergetics; later studies demonstrated its presence in other subcellular fractions and in blood plasma, and extensively investigated its antioxidant role. These 2 functions constitute the basis for supporting the clinical use of CoQ 〈 sub 〉 10 〈 /sub 〉 . Also, at the inner mitochondrial membrane level, CoQ 〈 sub 〉 10 〈 /sub 〉 is recognized as an obligatory cofactor for the function of uncoupling proteins and a modulator of the mitochondrial transition pore. Furthermore, recent data indicate that CoQ 〈 sub 〉 10 〈 /sub 〉 affects the expression of genes involved in human cell signaling, metabolism and transport, and some of the effects of CoQ 〈 sub 〉 10 〈 /sub 〉 supplementation may be due to this property. CoQ 〈 sub 〉 10 〈 /sub 〉 deficiencies are due to autosomal recessive mutations, mitochondrial diseases, aging-related oxidative stress and carcinogenesis processes, and also statin treatment. Many neurodegenerative disorders, diabetes, cancer, and muscular and cardiovascular diseases have been associated with low CoQ 〈 sub 〉 10 〈 /sub 〉 levels as well as different ataxias and encephalomyopathies. CoQ 〈 sub 〉 10 〈 /sub 〉 treatment does not cause serious adverse effects in humans and new formulations have been developed that increase CoQ 〈 sub 〉 10 〈 /sub 〉 absorption and tissue distribution. Oral administration of CoQ 〈 sub 〉 10 〈 /sub 〉 is a frequent antioxidant strategy in many diseases that may provide a significant symptomatic benefit.
Type of Medium:
Online Resource
ISSN:
1661-8769
,
1661-8777
Language:
English
Publisher:
S. Karger AG
Publication Date:
2014
detail.hit.zdb_id:
2546218-0
Permalink